Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) beat Wall Street’s revenue expectations in Q3 2026, with sales up 27.6% year on year to $290.8 million. The company expects the full year’s revenue to be around $1.11 billion, close to analysts’ estimates. Its non-GAAP profit of $2.70 per share was 23.8% above analysts’ consensus estimates.

Is now the time to buy ANIP? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

ANI Pharmaceuticals delivered a strong third quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, with robust year-over-year growth across its rare disease and generics businesses. Management credited the quarter’s performance to the successful expansion of its Cortrophin Gel into new indications such as acute gouty arthritis flares, as well as steady momentum in its legacy specialties. CEO Nikhil Lalwani highlighted that, although demand for Cortrophin was high, a surge in new patient cases strained the specialty pharmacy network, leading to delayed revenue conversion and prompting revisions to Cortrophin’s full-year outlook. The company also announced the proposed acquisition of Egetis Therapeutics, which is expected to further diversify its rare disease portfolio.

Looking ahead, management’s updated guidance is shaped by both operational adjustments and the strategic addition of Egetis Therapeutics. The company expects near-term investments in expanding its specialty pharmacy capacity and patient support teams to address existing bottlenecks and improve therapy conversion rates. CEO Nikhil Lalwani emphasized, “We are already seeing improvements in time to therapy and remain confident in the multi-year growth trajectory for Cortrophin and our rare disease pipeline.” The launch of EMCITATE, a newly approved therapy for MCT8 deficiency, is anticipated to provide a new growth driver, with efforts focused on increasing disease awareness, diagnosis, and payer coverage as part of the integration plan.

Key insights from management’s remarks

Management attributed the quarter’s results to strong demand for Cortrophin Gel, successful generics launches, and the initial steps toward expanding into rare disease markets through the pending Egetis acquisition.

• Cortrophin demand outpaces infrastructure: The expansion into gout indications led to a sharp rise in new patient cases, overwhelming the specialty pharmacy network and delaying revenue conversion despite robust underlying demand.

• Generics and product launches: ANI launched 16 new generics year-to-date, maintaining its position as a leader in complex generics filings and approvals, with these launches contributing to 11% year-over-year generics revenue growth.

• Egetis Therapeutics acquisition: The offer to acquire Egetis adds EMCITATE, the first approved treatment for MCT8 deficiency, to ANI’s portfolio, broadening its rare disease footprint and leveraging its established commercial infrastructure. EMCITATE’s launch is expected to provide a durable growth opportunity, with orphan exclusivity and patent protection into 2045.

• Specialty pharmacy network investments: Management responded to capacity constraints by expanding both the specialty pharmacy network and patient support teams, aiming to reduce bottlenecks and improve the conversion of prescriptions to filled therapies.

• Share repurchase activity: ANI repurchased $20 million in shares under an existing authorization, reflecting ongoing capital allocation discipline while supporting strategic investments and acquisitions.

Drivers of future performance

Management’s outlook centers on resolving operational bottlenecks, integrating the Egetis acquisition, and capturing additional growth in rare disease and generics.

• Operational improvements in Cortrophin: The company is increasing investments in patient support and specialty pharmacy capacity to accelerate therapy initiation and improve prescription fulfillment, which management believes will support sustained revenue growth in coming quarters.

• EMCITATE launch and rare disease expansion: Management expects the newly acquired EMCITATE to drive incremental revenues as diagnosis rates and patient identification increase, particularly through disease education and expanded access programs targeting under-diagnosed populations.

• Generics momentum and pipeline execution: Continued new product launches and investments in generics R&D are positioned to bolster ANI’s base business performance, supporting cash flows for rare disease initiatives and offsetting potential market or margin headwinds.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be watching (1) the pace at which ANI resolves specialty pharmacy and fulfillment bottlenecks for Cortrophin Gel, (2) the execution of the EMCITATE U.S. launch, including conversion of expanded access patients and expanded diagnosis efforts, and (3) the sustainability of generics revenue growth as new launches mature. Progress in integrating Egetis and expanding the rare disease business will also be key markers for the company’s long-term trajectory.

ANI Pharmaceuticals currently trades at $69.68, down from $71.65 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.